Member LoginDividend CushionValue Trap |
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Jun 16, 2017
Amazon To Buy Whole Foods: Not Creative Destruction, Just Destruction
Image Source: Mike Mozart. Amazon announced plans to buy Whole Foods. We’re viewing the news as affirmation of our decision to stay largely away from retail exposure in the newsletter portfolios. We think a bidding war for Whole Foods is possible, mostly to keep it and its real estate out of the hands of Amazon, potentially setting up for a true “winner’s curse” scenario. The winner will overpay. Jun 10, 2017
Glossary of Valuentum Terms
Image Source: Courtney Collison. We define the sections and proprietary metrics found in Valuentum's stock reports. Jun 8, 2017
Verint’s Cyber Intelligence Division Impresses
Image Source: Blogtrepreneur. One of the latest additions to the Best Ideas Newsletter portfolio experienced strong top-line growth in both of its operating segments during the first quarter, and we continue to like the company’s exposure to the cyber intelligence arena. May 31, 2017
Nevro: An Exciting But Risky Medtech Idea in the Early Stages of Its Growth
Image Source: Nevro. Innovation continues to thrive in the medical field. The rapid aging of the industrialized world’s population bodes well for rising demand. Let’s look at a promising med tech idea, which we believe offers explosive growth in the field of Neuromodulation. It's a risky one though. May 26, 2017
Alexion’s Executive Departures and an Update from Regeneron Pharma
Image shown above: Performance of Regeneron since the summer of 2013.An executive scandal continues to mar the performance of Alexion Pharmaceuticals. The CFO has resigned his position effective the end of August, but there is more to this story. Let’s also talk Regeneron. May 25, 2017
Alerts – Spring Cleaning in the Newsletter Portfolios
We’re making a number of changes to the newsletter portfolios. May 25, 2017
Subscribe to Valuentum by Credit or Debit Card
View this article to subscribe to Valuentum by credit card. May 24, 2017
Changing Millennial Preferences and the Death of the Blue Box?
Image Source: samantha celera. The widely-held thesis that the ultra-rich care more about status than function may be waning as convergence between the two ensue. Let's talk Tiffany and the ultra-luxury space. May 24, 2017
Pipeline Woes Continue to Plague Amgen
Image Source: kibbles_bits. The commercial viability of a biotech outfit’s pipeline can often determine the future path of the share price. Irrespective of the past performance, if a company cannot innovate, it will witness its competitive position erode, leading to an inevitable decline in revenue. The latest setback from the clinical labs continues to support a bearish stance on Amgen. May 23, 2017
Cracker Barrel Hits the Trifecta!
Image Source: Mike Mozart. Cracker Barrel increased its full-year earnings guidance, raised its regular dividend, and issued a special payout. The market was pleased.
prev12345678910111213141516171819202122232425
26272829303132333435363738394041424344454647484950 51525354555657585960616263646566676869707172737475 767778798081828384858687888990919293949596979899100 101102103104105106107108109110111112113114115116117118119120 121122123124125126127128129130131132133134135136137138139140 141142143144145146147148149150151152153154155156157158159160 161162163164165166167168169170171172173174175176177178179180 181182183184185186187188189190191192193194195196197198199200 201202203204205206207208209210211212213214215216217218219220 221222223224225226227228229230231232233234235236237238239240 241242243244245246247248249250251252253254255256257258259260 261262263264265266267268269270271272273274275276277278279280 281282283next The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|